The authors ended their paper by suggesting that SIRT1 is a promising target for the development of novel therapeutics for osteoporosis.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Reference
- Zainabadi K, Liu CJ, Caldwell ALM, et al. SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS One. 2017 Sep 22;12(9):e0185236. doi: 10.1371/journal.pone.0185236. eCollection 2017.